PubRank

Lisa R Tannock

Author PubWeight™ 27.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 2004 1.73
2 SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest 2008 1.48
3 HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol 2008 1.40
4 Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol 2008 1.11
5 A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring) 2009 1.10
6 Serum amyloid A in atherosclerosis. Curr Opin Lipidol 2011 1.09
7 Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res 2007 1.08
8 Clinical efficacy and patient satisfaction with U-500 insulin use. Diabetes Res Clin Pract 2010 1.04
9 Thiol oxidative stress induced by metabolic disorders amplifies macrophage chemotactic responses and accelerates atherogenesis and kidney injury in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2009 1.02
10 Transforming growth factor-β regulation of proteoglycan synthesis in vascular smooth muscle: contribution to lipid binding and accelerated atherosclerosis in diabetes. J Diabetes 2010 0.99
11 Köbberling type of familial partial lipodystrophy: an underrecognized syndrome. Diabetes Care 2003 0.95
12 Deficiency of endogenous acute phase serum amyloid A does not affect atherosclerotic lesions in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2013 0.91
13 Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus. Curr Diab Rep 2011 0.90
14 Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy. Am J Pathol 2011 0.88
15 Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res Clin Pract 2007 0.87
16 Decreased body fat, elevated plasma transforming growth factor-β levels, and impaired BMP4-like signaling in biglycan-deficient mice. Connect Tissue Res 2012 0.85
17 Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med 2009 0.84
18 Prevention of TGFβ induction attenuates angII-stimulated vascular biglycan and atherosclerosis in Ldlr-/- mice. J Lipid Res 2013 0.82
19 Regulation of vascular proteoglycan synthesis by metabolic factors associated with diabetes. J Investig Med 2007 0.82
20 Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. Postgrad Med 2010 0.82
21 Serum amyloid A is found on ApoB-containing lipoproteins in obese humans with diabetes. Obesity (Silver Spring) 2013 0.82
22 Endogenous androgen deficiency enhances diet-induced hypercholesterolemia and atherosclerosis in low-density lipoprotein receptor-deficient mice. Gend Med 2012 0.81
23 Statin-exposed vascular smooth muscle cells secrete proteoglycans with decreased binding affinity for LDL. J Lipid Res 2003 0.81
24 Glucosamine inhibits the synthesis of glycosaminoglycan chains on vascular smooth muscle cell proteoglycans by depletion of ATP. Arch Physiol Biochem 2008 0.81
25 Durability of glycemic control using U-500 insulin. Diabetes Res Clin Pract 2011 0.80
26 Reversibility of renal injury with cholesterol lowering in hyperlipidemic diabetic mice. J Lipid Res 2010 0.79
27 Management of new-onset diabetes mellitus after transplantation. Postgrad Med 2008 0.76
28 METABOLIC EFFECTS OF HORMONE THERAPY IN TRANSGENDER PATIENTS. Endocr Pract 2015 0.75
29 U-500: a convenient insulin for a convenience food nation. Endocr Pract 2013 0.75
30 Role of dyslipidemia in patients with chronic kidney disease. Postgrad Med 2013 0.75